JP2024500616A - オメカムチブメカルビルの投与により心不全を処置する方法 - Google Patents

オメカムチブメカルビルの投与により心不全を処置する方法 Download PDF

Info

Publication number
JP2024500616A
JP2024500616A JP2023528276A JP2023528276A JP2024500616A JP 2024500616 A JP2024500616 A JP 2024500616A JP 2023528276 A JP2023528276 A JP 2023528276A JP 2023528276 A JP2023528276 A JP 2023528276A JP 2024500616 A JP2024500616 A JP 2024500616A
Authority
JP
Japan
Prior art keywords
patient
heart failure
omecamtibumecarbil
less
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023528276A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024500616A5 (https=
Inventor
ナリモン ホナルポウル，
ファディー マリク，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of JP2024500616A publication Critical patent/JP2024500616A/ja
Publication of JP2024500616A5 publication Critical patent/JP2024500616A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/38—Applying electric currents by contact electrodes alternating or intermittent currents for producing shock effects
    • A61N1/39—Heart defibrillators
    • A61N1/3956—Implantable devices for applying electric shocks to the heart, e.g. for cardioversion
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Radiology & Medical Imaging (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
JP2023528276A 2020-11-12 2021-11-11 オメカムチブメカルビルの投与により心不全を処置する方法 Pending JP2024500616A (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US202063112995P 2020-11-12 2020-11-12
US63/112,995 2020-11-12
US202163154077P 2021-02-26 2021-02-26
US63/154,077 2021-02-26
US202163187084P 2021-05-11 2021-05-11
US63/187,084 2021-05-11
US202163202873P 2021-06-28 2021-06-28
US63/202,873 2021-06-28
US202163203436P 2021-07-22 2021-07-22
US63/203,436 2021-07-22
PCT/US2021/058988 WO2022103966A1 (en) 2020-11-12 2021-11-11 Methods of treating heart failure by administering omecamtiv mecarbil

Publications (2)

Publication Number Publication Date
JP2024500616A true JP2024500616A (ja) 2024-01-10
JP2024500616A5 JP2024500616A5 (https=) 2024-11-12

Family

ID=78822539

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023528276A Pending JP2024500616A (ja) 2020-11-12 2021-11-11 オメカムチブメカルビルの投与により心不全を処置する方法

Country Status (22)

Country Link
US (2) US12194039B2 (https=)
EP (2) EP4243825B1 (https=)
JP (1) JP2024500616A (https=)
KR (1) KR20230107282A (https=)
AU (1) AU2021380754A1 (https=)
CA (1) CA3200673A1 (https=)
CL (2) CL2023001351A1 (https=)
DK (1) DK4243825T3 (https=)
ES (1) ES3060408T3 (https=)
FI (1) FI4243825T3 (https=)
HR (1) HRP20251568T1 (https=)
IL (1) IL302850A (https=)
LT (1) LT4243825T (https=)
MX (1) MX2023005455A (https=)
NZ (1) NZ800220A (https=)
PL (1) PL4243825T3 (https=)
PT (1) PT4243825T (https=)
RS (1) RS67558B1 (https=)
SI (1) SI4243825T1 (https=)
SM (1) SMT202600073T1 (https=)
TW (1) TW202233189A (https=)
WO (1) WO2022103966A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2522579T3 (es) 2004-06-17 2014-11-17 Cytokinetics, Inc. Compuestos, composiciones y métodos
SG11201507258PA (en) 2013-03-14 2015-10-29 Amgen Inc Heterocyclic compounds and their uses
AU2018294254C1 (en) 2017-06-30 2022-10-13 Amgen Inc. Synthesis of omecamtiv mecarbil
DK3645002T3 (da) 2017-06-30 2024-12-16 Amgen Inc Fremgangsmåder til behandling af hjertesvigt med hjerte-sarkomer-aktivatorer
PT3594199T (pt) 2018-07-09 2020-09-04 Amgen Inc 2-fluoro-3-nitrotolueno cristalino e processo para a sua preparação
MA53226A (fr) 2018-08-17 2021-11-24 Amgen Inc Sel et formes cristallines d'omecamtiv mecarbil
WO2020131574A1 (en) 2018-12-18 2020-06-25 Amgen Inc. Method of reducing aromatic nitro compounds
DK4243825T3 (da) 2020-11-12 2025-12-01 Amgen Inc Omecamtiv mecarbil til behandling af hjerteinsattsvigt hos udvalgte patientgrupper
IL305751A (en) 2021-03-10 2023-11-01 Amgen Inc SYNTHESIS OF OMECAMTIV MECARBIL
US20250161298A1 (en) * 2022-02-22 2025-05-22 Yale University Methods of treating, ameliorating, or preventing heart failure, and methods of promoting heart muscle growth
WO2024081611A1 (en) * 2022-10-11 2024-04-18 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators
US11986474B1 (en) 2023-06-27 2024-05-21 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators
WO2026050494A1 (en) * 2024-08-29 2026-03-05 Cytokinetics, Incorporated Omecamtiv mecarbil for use in treating heart failure by activating cardiac sarcomere

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020526483A (ja) * 2017-06-30 2020-08-31 アムジエン・インコーポレーテツド 心筋節活性化剤で心不全を治療する方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4450150A (en) 1973-05-17 1984-05-22 Arthur D. Little, Inc. Biodegradable, implantable drug delivery depots, and method for preparing and using the same
EP1053752A1 (en) 1998-02-10 2000-11-22 Yoshitomi Pharmaceutical Industries, Ltd. Preparations with controlled release
GB2344287A (en) 1998-12-03 2000-06-07 Ferring Bv Controlled release pharmaceutical formulation
AU2003279842A1 (en) 2002-10-04 2004-05-04 Microchips, Inc. Medical device for controlled drug delivery and cardiac monitoring and/or stimulation
ES2522579T3 (es) 2004-06-17 2014-11-17 Cytokinetics, Inc. Compuestos, composiciones y métodos
ES2419007T3 (es) 2005-12-15 2013-08-19 Cytokinetics, Inc. Ciertas entidades químicas, composiciones y procedimientos
US20080031957A1 (en) 2006-05-15 2008-02-07 Deluca Hector F Pulmonary delivery of 1alpha,25-dihydroxyvitamin D3 and co-administration of parathyroid hormone or calcitonin
FR2902092B1 (fr) 2006-06-07 2008-09-05 Sapelem Soc Par Actions Simpli Appareil de manutention de charge
WO2008130158A1 (en) 2007-04-19 2008-10-30 Dong-A Pharmaceutical. Co., Ltd A biodegradable microsphere composition suitable for the controlled release of glucose controlling peptide and formulation thereof
US9895308B2 (en) 2013-03-14 2018-02-20 Amgen Inc. Heterocyclic compounds and their uses
SG11201507258PA (en) 2013-03-14 2015-10-29 Amgen Inc Heterocyclic compounds and their uses
EP3250557B1 (en) 2015-01-29 2024-11-20 Signal Pharmaceuticals, LLC Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
US10543215B2 (en) 2015-06-26 2020-01-28 Amgen Inc. Combination therapy of cardiac myosin activator and sinus node if current inhibitor
CA3052625A1 (en) 2017-02-06 2018-08-09 Acceleron Pharma Inc. Compositions and methods for treating heart failure
AU2018294254C1 (en) 2017-06-30 2022-10-13 Amgen Inc. Synthesis of omecamtiv mecarbil
PT3594199T (pt) 2018-07-09 2020-09-04 Amgen Inc 2-fluoro-3-nitrotolueno cristalino e processo para a sua preparação
EP3820851A1 (en) 2018-07-12 2021-05-19 Assia Chemical Industries Ltd Solid state forms of omecamtiv mecarbil & omecamtiv mecarbil dihcl
FI3599243T3 (fi) 2018-07-26 2023-06-22 Cvie Therapeutics Ltd 17beeta-heterosyklyylidigitaliksen kaltaisia yhdisteitä sydämen vajaatoiminnan hoitoon
MA53226A (fr) 2018-08-17 2021-11-24 Amgen Inc Sel et formes cristallines d'omecamtiv mecarbil
WO2020131574A1 (en) 2018-12-18 2020-06-25 Amgen Inc. Method of reducing aromatic nitro compounds
MX2021010483A (es) 2019-03-05 2021-10-01 Windtree Therapeutics Inc Formulacion intravenosa que contiene istaroxima para el tratamiento de insuficiencia cardiaca aguda (ahf).
WO2021053175A1 (en) 2019-09-19 2021-03-25 Synthon B.V. Salts of omecamtiv mecarbil and solid forms thereof
EP4031541A1 (en) 2019-09-19 2022-07-27 Synthon B.V. Salts of omecamtiv mecarbil and solid forms thereof
EP4041710A1 (en) 2019-10-09 2022-08-17 Dr. Reddy's Laboratories Limited Alternate processes for the preparation of omecamtiv mecarbil
WO2021070123A1 (en) 2019-10-09 2021-04-15 Dr. Reddy’S Laboratories Limited Solid forms of omecamtiv mecarbil dihydrochloride and processes thereof
EP4054588A4 (en) 2019-11-10 2023-12-13 MyoKardia, Inc. Methods of treatment with myosin modulator
GB201918853D0 (en) 2019-12-19 2020-02-05 Lund Lars H Methods of treatment
CN114929671B (zh) 2020-01-03 2024-04-16 苏州科睿思制药有限公司 化合物i二盐酸盐的共晶及其制备方法和用途
US20230090391A1 (en) 2020-02-10 2023-03-23 Amgen Inc. Omecamtiv mecarbil tablet
DK4243825T3 (da) 2020-11-12 2025-12-01 Amgen Inc Omecamtiv mecarbil til behandling af hjerteinsattsvigt hos udvalgte patientgrupper
IL305751A (en) 2021-03-10 2023-11-01 Amgen Inc SYNTHESIS OF OMECAMTIV MECARBIL
WO2023205291A2 (en) 2022-04-21 2023-10-26 The Board Of Regents Of The University Of Oklahoma Targeting myocardial tissue for delivery of therapeutic and imaging agents
WO2024081611A1 (en) 2022-10-11 2024-04-18 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators
US11986474B1 (en) 2023-06-27 2024-05-21 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020526483A (ja) * 2017-06-30 2020-08-31 アムジエン・インコーポレーテツド 心筋節活性化剤で心不全を治療する方法

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
"Registrational Study With Omecamtiv Mecarbil (AMG 423) to Treat Chronic Heart Failure With Reduced E", CLINICALTRIALS.GOV ID NCT02929329, JPN6025049154, 7 October 2016 (2016-10-07), ISSN: 0005836381 *
DRUGS OF THE FUTURE, vol. 34, no. 12, JPN6026014009, 2009, pages 950, ISSN: 0005836377 *
EUROPEAN JOURNAL OF HEART FAILURE, vol. 22(11), JPN6025049156, 2020, pages 2160 - 2171, ISSN: 0005836379 *
EXPERT OPINION ON INVESTIGATIONAL DRUGS, vol. 25(1), JPN6025049155, 2016, pages 117 - 127, ISSN: 0005836380 *
JACC HEART FAIL., vol. 3, no. 1, JPN6026014008, 2015, pages 22 - 29, ISSN: 0005836375 *
JACC:HEART FAILURE, vol. Vol.8,Issue4, JPN6025049153, 2020, pages 329 - 340, ISSN: 0005741860 *
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, vol. Vol.73,Issue9, JPN6026014010, 2019, pages 691, ISSN: 0005836376 *
LANCET, vol. 378, JPN6025049152, 2011, pages 676 - 683, ISSN: 0005836374 *
LANCET, vol. 388, JPN6025049151, 2016, pages 2895 - 2903, ISSN: 0005836382 *

Also Published As

Publication number Publication date
LT4243825T (lt) 2026-01-12
WO2022103966A1 (en) 2022-05-19
WO2022103966A9 (en) 2022-08-18
US12194039B2 (en) 2025-01-14
SI4243825T1 (sl) 2026-01-30
EP4706638A3 (en) 2026-04-22
AU2021380754A9 (en) 2024-10-24
PT4243825T (pt) 2026-01-30
CL2023001351A1 (es) 2023-10-20
DK4243825T3 (da) 2025-12-01
MX2023005455A (es) 2023-07-27
EP4706638A2 (en) 2026-03-11
SMT202600073T1 (it) 2026-03-09
PL4243825T3 (pl) 2026-03-23
CA3200673A1 (en) 2022-05-19
HRP20251568T1 (hr) 2026-03-13
EP4243825B1 (en) 2025-11-12
RS67558B1 (sr) 2026-01-30
KR20230107282A (ko) 2023-07-14
IL302850A (en) 2023-07-01
NZ800220A (en) 2026-02-27
FI4243825T3 (fi) 2025-12-15
US20250205228A1 (en) 2025-06-26
ES3060408T3 (en) 2026-03-26
TW202233189A (zh) 2022-09-01
US20220184068A1 (en) 2022-06-16
AU2021380754A1 (en) 2023-06-22
EP4243825A1 (en) 2023-09-20
CL2024000466A1 (es) 2024-08-30

Similar Documents

Publication Publication Date Title
JP2024500616A (ja) オメカムチブメカルビルの投与により心不全を処置する方法
AU2024200991B2 (en) Methods of treating heart failure with cardiac sarcomere activators
Upadhya et al. Heart failure with preserved ejection fraction in older adults
2009 Writing Group to Review New Evidence and Update the 2005 Guideline for the Management of Patients with Chronic Heart Failure Writing on Behalf of the 2005 Heart Failure Writing Committee et al. 2009 focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation
WO2024081611A1 (en) Methods for treating heart failure by administering cardiac sarcomere activators
SHIMOYAMA et al. Docetaxel induced cardiotoxicity
HK40101740A (zh) 通过施用奥美卡替莫卡必尔治疗心力衰竭的方法
CN116710139A (zh) 通过施用奥美卡替莫卡必尔治疗心力衰竭的方法
Williford et al. Ischemic Heart Disease
Norgard et al. Pharmacotherapy for Heart Failure with Left Ventricular Dysfunction: Beyond Angiotensin‐Converting Enzyme Inhibitors and β‐Blockers
Pop et al. Benefits and Risks of Anticoagulation in Acute Coronary Syndrome
TW202602436A (zh) 用於治療心臟衰竭之醛固酮合成酶抑制劑
HK40028258A (en) Methods of treating heart failure with cardiac sarcomere activators
HK40028258B (en) Methods of treating heart failure with cardiac sarcomere activators
Usman et al. Stable Coronary Artery Disease
Nguyen et al. ST Segment Elevation Myocardial Infarction
Truc et al. Stable Coronary Artery Disease
MacGregor et al. Raised blood pressure: the biggest cause of premature death and disability in men?

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241101

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241101

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20251007

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260227

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260408